Serial measurement of circulating cardiovascular-enriched microRNAs in patients with ischaemic heart disease – a five-year longitudinal study
Open Access
- 23 December 2025
- journal article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 45 (12) , 809-814
Abstract
Patients with ischaemic heart disease (IHD) require frequent monitoring, as the transition from stable disease to acute life-threatening events remains largely unpredictable. MicroRNAs (miRNAs), small non-coding RNAs involved in physiological and pathological processes, are released into circulation and remain stable. In this study, we aimed to determine if the serial measurement of cardiovascular-enriched circulating miRNAs could reflect changes in cardiac function in patients with IHD. Fifty-three new IHD patients participated in a five-year study with regular echocardiography, blood tests and follow-ups at 12-month intervals, with 25 followed up at five years. Serial echocardiography revealed a pattern towards worsening diastolic function over the follow-up period. RT-PCR analysis was conducted on four cardiovascular-enriched circulating miRNAs: miR-1, miR-126, miR-132 and miR-34a. Among these, only miR-1 and miR-126 showed statistically significant down-regulation starting from 24 months onwards. Linear mixed models, adjusted for body mass index and HbA1c changes, indicated significant associations between fold changes in miR-1 and miR-34a with cardiac function changes. Results from this first-ever five-year follow-up study have identified a possible link between cardiovascular-enriched miRNAs, miR-1 and -34a and cardiac function in patients with IHD, providing a foundation for prognostic tests for IHD and laying the foundation for further studies in larger populations. It is noteworthy that a significant dropout of participants may have impacted the statistical power in our study.Keywords
This publication has 14 references indexed in Scilit:
- MicroRNA-126: A key regulator of angiogenesis, inflammation, and tumorigenesis — Exploring its multifaceted functions in vascular health and cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- MicroRNAs: Diagnostic, Prognostic and Therapeutic Role in Heart Failure—a ReviewESC Heart Failure, 2022
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicityJournal of Applied Toxicology, 2022
- Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart AssociationCirculation, 2022
- Diabetes induces dysregulation of microRNAs associated with survival, proliferation and self-renewal in cardiac progenitor cellsDiabetologia, 2021
- Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cellsCell Death & Differentiation, 2018
- Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathyCardiovascular Research, 2017
- Differential expression pattern of cardiovascular microRNAs in the human type-2 diabetic heart with normal ejection fractionInternational Journal of Cardiology, 2016
- MicroRNA Signatures Differentiate Preserved from Reduced Ejection Fraction Heart FailureEuropean Journal of Heart Failure, 2015
- The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagyNature Communications, 2012